STAT+: Supreme Court agrees to review ‘skinny labeling’ and generic drug access
The Supreme Court agreed to review a controversy over so-called skinny labels for medicines, a decision that will be closely watched for its implications for the availability of generic medicines.
Espace publicitaire · 300×250